The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.